Navigation Links
Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
Date:2/5/2008

WASHINGTON, February 5, 2008 Researchers are identifying innovative therapeutics for sickle cell anemia that focus on specific factors in the disease's progression, such as the important role of hydration of the red blood cells. According to a study prepublished online in Blood, the official journal of the American Society of Hematology, a novel small molecule therapy called senicapoc showed efficacy in maintaining hydration of red blood cells and increasing hemoglobin levels in patients with sickle cell anemia. Sickle cell anemia affects about 70,000 Americans, and millions worldwide.

Sickle cell anemia (the most common form of sickle cell disease, or SCD) is a serious chronic condition in which the red blood cells (RBCs) can become sickle-shaped upon deoxygenation (shaped like a "C"). Because of their shape, rigidity, and tendency to stick to blood vessel walls, the cells do not move easily through the vessels and can form clumps, which may lead to blocked blood flow and pain, infections, or organ damage. Research suggests that dehydration of the RBCs is one of the key contributors to the deformed shape and affects the levels of circulating hemoglobin, an important determinant of oxygen delivery throughout the body. The dehydration appears to result from loss of potassium via two pathways, one of which is known as the Gardos channel. It has been suggested that a therapy designed to block this channel might have a beneficial effect on the progression of the disease.

Senicapoc, a known Gardos channel blocker, works by limiting solute and water loss, thereby preserving RBC hydration. Previous studies have shown that senicapoc prevents the loss of potassium from the RBCs, is well tolerated, and has favorable pharmacokinetics with a long half-life, permitting once-daily dosing.

In a 12-week, multicenter, phase II, randomized, double-blind, dose-finding study, senicapoc was evaluated for its effect on hemoglobin level and markers of RBC destruction (hemolysis) in SCD patients. The investigators also sought to obtain additional safety data and identify the optimal dose for a phase III study. The primary efficacy endpoint was the change in blood hemoglobin level from baseline to end of study, and secondary endpoints included markers of hemolysis, changes in RBC count and indices, and frequency of painful events or "crises."

"An understanding of the pathophysiology of sickle cell disease is extremely important in order to identify new therapeutic targets," said Kenneth Ataga, MD, of the Division of Hematology/ Oncology at the University of North Carolina at Chapel Hill and lead author of the study.

A total of 90 eligible patients were enrolled in the trial. Of these participants, 24 were also taking hydroxyurea, a drug already approved for the treatment of SCD. The patients were randomized into three treatment arms: placebo (n=30), low-dose senicapoc (6 mg/day, n=29), and high-dose senicapoc (10 mg/day, n=31). Safety and efficacy assessments were obtained at the end of week one and then every two weeks until completion of the study treatment.

Patients treated with senicapoc achieved measurable improvements in hemoglobin levels. Patients in the high-dose senicapoc arm achieved a hemoglobin increase of 0.68 g/dL (vs. 0.01 g/dL for patients taking placebo). The team also found corresponding increases in hematocrit and RBC count in the patients taking senicapoc when compared to placebo. Notably, the sub-groups of patients taking hydroxyurea achieved similar results. In the low-dose group, the increase in hemoglobin compared to placebo was not statistically significant.

Treatment with senicapoc also produced dose-dependent and statistically significant improvements in secondary endpoints, including the percentage of dense RBCs (-2.41 vs. -0.08, high-dose vs. placebo), reticulocytes (-4.12 vs. -0.46), and lactate dehydrogenase (-121 vs. -15), a marker of hemolysis. There were no differences among the treatment groups in the overall frequency of painful crises, though crises experiences were infrequent in this study.

Senicapoc was safe and well tolerated in the study. Ten patients, five of whom were in the placebo group, discontinued the study early. Three patients dropped out due to adverse events: one in the low-dose group for weakness and shortness of breath, and two in the high-dose group for pain crises and acute chest syndrome. The most common serious adverse effect (SAE) was pain crisis, followed by pneumonia and acute chest syndrome, with a similar incidence across the active and placebo arms. None of the SAEs were thought attributable to senicapoc.

"The results we saw in this study provide further evidence that blocking the Gardos channel reduces dehydration of the sickle erythrocytes and thus supports the hypothesis that this type of approach may lead to an amelioration of the anemic state in patients with sickle cell anemia," said Dr. Ataga. "As noted in the paper, a Phase III study of senicapoc in SCD patients was recently terminated due to the low probability of achieving a reduction in crisis rate, the primary endpoint of that study. Clearly, further work is necessary to understand how the reduction in RBC dehydration and hemolysis demonstrated from the results of this Phase II study impacts the complex pathophysiology of sickle cell disease."


'/>"/>
Contact: Laura Stark
lstark@hematology.org
202-776-0544
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Novel vaccine concept developed by scientists at the Wistar Institute
2. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
3. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
4. Statement by AARP CEO Bill Novelli on President Bushs State of the Union
5. New method enables design, production of extremely novel drugs
6. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
7. Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi-Electrode Ablation System
8. Novel anticancer strategy moves from laboratory to clinic
9. FDA approves Bystolic, a novel beta blocker
10. Fitness Guru Offers Novel Exercise Program and Tips to Stick with Exercise in the New Year
11. Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Columbus, Ohio (PRWEB) , ... March 28, 2017 , ... ... City was selected as one of few medical professionals in the country to sit ... As Founder of Juvly Aesthetics, in just 2 years Dr. Harper helped propel the ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... GA (PRWEB) , ... March 28, 2017 , ... With ... to Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville ... location since 2016. The new office allows opportunity for transition of Patten Seed operations ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who ... 8-10. , This event was exclusive to providers and offered an opportunity to ... took place at the Manchester Grand Hyatt where attendees gathered for a lively discussion ...
(Date:3/28/2017)... ... March 28, 2017 , ... Bacteria and fungi are probably not the first ingredients that ... fact, including the right microorganisms in your diet can actually improve health outcomes. And the ... This is the topic of a new peer-reviewed paper led by Maria ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... , March 27, 2017  A new survey ... found that Medicare,s Competitive Bidding Program (CBP) significantly reduced ... supplies. The lack of choice forces beneficiaries to switch ... dire health consequences. AADE,s survey is ... AADE and others pointing out the inherent problems with ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 FinancialBuzz.com ... According to a ... North America , grew 34 percent to $6.7 billion ... growth rate of (CAGR) over the next five years, from $6.7 billion ... portion of Americans that will be able to purchase cannabis without a ...
Breaking Medicine Technology: